Compounded Medication – Prescription Only

This product is a compounded orally disintegrating tablet (ODT) formulation containing semaglutide and is dispensed only pursuant to a valid prescription issued by a licensed healthcare provider. Semaglutide is a synthetic peptide that acts as a glucagon-like peptide-1 (GLP-1) receptor agonist. In compounding practice, semaglutide formulations may be prescribed when a provider determines that individualized concentration, formulation, or dosing considerations are clinically appropriate for a specific patient. This product is not available for self-selection and may only be dispensed following provider authorization.

Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). The FDA does not evaluate compounded formulations for safety, effectiveness, or quality. Compounding is performed by a state-licensed pharmacy pursuant to a patient-specific prescription. This page provides general, non-therapeutic information for educational and compliance purposes only. It does not describe intended use, therapeutic benefit, weight-related outcomes, appetite effects, glycemic control, or expected clinical results.

General Scientific Information (Non-Therapeutic)

Semaglutide has been studied in scientific and clinical research for its molecular structure and activity at the GLP-1 receptor. GLP-1 receptor agonists have been examined for their role in endocrine signaling pathways under controlled research conditions. Descriptions of receptor interactions or biochemical characteristics are provided solely for general scientific context. No claims are made regarding safety, effectiveness, metabolic outcomes, weight change, appetite modulation, or suitability for any particular condition.

Formulation Considerations

Compounded formulations of semaglutide may be prepared in different concentrations or delivery formats as determined by the prescribing healthcare provider. These variations reflect formulation preferences or individual patient considerations and do not alter the regulatory status of the compounded medication. Differences in formulation do not imply enhanced effectiveness or altered clinical outcomes.

Contraindications

Semaglutide ODT should not be used in individuals who have a known hypersensitivity or allergy to semaglutide or any component of the compounded formulation; have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2); have experienced prior serious adverse reactions to GLP-1 receptor agonists; or have other conditions in which GLP-1 receptor agonist therapy is contraindicated as determined by the prescribing healthcare provider. Use in pregnant or breastfeeding individuals should occur only if a licensed healthcare provider determines that potential risks and benefits have been carefully evaluated.

Warnings and Precautions

GLP-1 receptor agonists may be associated with gastrointestinal effects and other systemic reactions. Caution is advised in individuals with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease, or renal impairment. This orally disintegrating tablet should be used only as prescribed by a licensed healthcare provider. Patients should inform their healthcare provider of all medical conditions, medications, and supplements prior to receiving this compounded formulation.

Potential Side Effects

Reported side effects associated with GLP-1 receptor agonist formulations may include nausea, vomiting, diarrhea, constipation, abdominal discomfort, headache, dizziness, or fatigue. Serious adverse reactions are uncommon but may occur. Patients should seek immediate medical attention if they experience severe abdominal pain, symptoms suggestive of pancreatitis, signs of a severe allergic reaction, or other unexpected systemic symptoms.